

# Huiping Li

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3990914/publications.pdf>

Version: 2024-02-01

61  
papers

1,048  
citations

623734

14  
h-index

477307

29  
g-index

64  
all docs

64  
docs citations

64  
times ranked

1740  
citing authors

#	ARTICLE	IF	CITATIONS
1	The efficacy and safety of palbociclib combined with endocrine therapy in patients with hormone receptor-positive HER2-negative advanced breast cancer: a multi-center retrospective analysis. <i>Anti-Cancer Drugs</i> , 2022, 33, e635-e643.	1.4	4
2	Abstract P2-13-31: Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial. <i>Cancer Research</i> , 2022, 82, P2-13-31-P2-13-31.	0.9	1
3	Germline Mutational Landscape in Chinese Patients With Advanced Breast Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 745796.	2.8	1
4	Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients. <i>Journal of Translational Medicine</i> , 2022, 20, 211.	4.4	8
5	A multicenter, randomized, double-blind, phase III trial comparing denosumab biosimilar QL1206 and denosumab in patients with bone metastases from solid tumors. <i>Journal of Clinical Oncology</i> , 2022, 40, 2526-2526.	1.6	0
6	Efficacy and safety of initial five years of adjuvant endocrine therapy in postmenopausal hormone receptor-positive breast cancer: A systematic review and network meta-analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 535-535.	1.6	0
7	A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 5539-5539.	1.6	1
8	Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study. <i>Journal of Clinical Oncology</i> , 2022, 40, 1031-1031.	1.6	4
9	Phase II randomized trial of different nab-paclitaxel dose schedule in patients with HER-2 negative recurrent/metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, e13050-e13050.	1.6	0
10	Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer: a systematic review and meta-analysis. <i>BMC Cancer</i> , 2021, 21, 149.	2.6	77
11	Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 396-402.	1.1	9
12	Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 131-141.	2.3	8
13	Prognostic Value of the TP53 Mutation Location in Metastatic Breast Cancer as Detected by Next-Generation Sequencing. <i>Cancer Management and Research</i> , 2021, Volume 13, 3303-3316.	1.9	5
14	Prognostic factors for patients with metastatic breast cancer: a literature review. <i>Translational Cancer Research</i> , 2021, 10, 1644-1655.	1.0	0
15	Incidence of neutropenia in breast cancer patients with administration of mecapegfilgrastim. <i>Journal of Clinical Oncology</i> , 2021, 39, e24070-e24070.	1.6	0
16	Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 608781.	2.8	5
17	Phase I Study and Pilot Efficacy Analysis of Entinostat, a Novel Histone Deacetylase Inhibitor, in Chinese Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 591-599.	3.6	6
18	Bilateral breast cancer in China: A 10-year single-center retrospective study (2006-2016). <i>Cancer Medicine</i> , 2021, 10, 6089-6098.	2.8	6

#	ARTICLE	IF	CITATIONS
19	Activity of preclinical and phase I clinical trial of a novel androgen receptor antagonist GT0918 in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 725-736.	2.5	4
20	Cell-free DNA comparative analysis of the genomic landscape of first-line hormone receptor-positive metastatic breast cancer from the US and China. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 213-226.	2.5	2
21	An Overview of the Treatment Efficacy and Side Effect Profile of Pharmacological Therapies in Asian Patients with Breast Cancer. <i>Targeted Oncology</i> , 2021, 16, 701-741.	3.6	7
22	Multicenter phase II study of apatinib single or combination therapy in HER2-negative breast cancer involving chest wall metastasis. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 243-255.	2.2	6
23	Response to Sung, Rosenberg, and Yang. <i>Journal of the National Cancer Institute</i> , 2020, 112, 547-548.	6.3	0
24	Efficacy and Safety of Fulvestrant 500mg in Hormone-receptor Positive Human Epidermal Receptor 2 Negative Advanced Breast Cancer: A Real-world Study in China. <i>Journal of Cancer</i> , 2020, 11, 6612-6622.	2.5	11
25	&lt;p&gt;Advances in the Detection Technologies and Clinical Applications of Circulating Tumor DNA in Metastatic Breast Cancer&lt;/p&gt;. <i>Cancer Management and Research</i> , 2020, Volume 12, 3547-3560.	1.9	13
26	Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 689-697.	2.5	25
27	&lt;p&gt;Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab&lt;/p&gt;. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 4385-4395.	2.0	6
28	Safety, tolerability, and preliminary pharmacokinetic/pharmacodynamic profile of JMT103 in patients with bone metastases from solid tumors: A multicenter, open-label, dose-escalation, phase I clinical study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3638.	1.6	9
29	Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 149-162.	2.2	12
30	Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2020, 32, 370-382.	2.2	18
31	Detection of ESR1 Mutations Based on Liquid Biopsy in Estrogen Receptor-Positive Metastatic Breast Cancer: Clinical Impacts and Prospects. <i>Frontiers in Oncology</i> , 2020, 10, 587671.	2.8	12
32	Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study. <i>Oncology Letters</i> , 2020, 20, 378.	1.8	1
33	Efficacy of lapatinib combined with capecitabine in patients with HER2- <sup>+</sup> positive metastatic breast cancer in a real-world study. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	6
34	Pyrotinib or Lapatinib Combined With Capecitabine in HER2- <sup>+</sup> Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2610-2619.	1.6	226
35	Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 178, 17-33.	2.5	74
36	Treating HR+/HER2- <sup>-</sup> breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	2.5	29

#	ARTICLE	IF	CITATIONS
37	Transferrin Functionization Elevates Transcytosis of Nanogranules across Epithelium by Triggering Polarity-Associated Transport Flow and Positive Cellular Feedback Loop. ACS Nano, 2019, 13, 5058-5076.	14.6	50
38	Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Technology in Cancer Research and Treatment, 2019, 18, 153303381982870.	1.9	26
39	Patterns of Use of Docetaxel-Containing Adjuvant Chemotherapy Among Chinese Patients with Operable Breast Cancer: A Multicenter Observational Study. Advances in Therapy, 2019, 36, 131-146.	2.9	4
40	An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 586-600.	2.2	10
41	Efficacy and safety of PEG-rhG-CSF in primary and secondary prevention of chemotherapy-induced neutropenia.. Journal of Clinical Oncology, 2019, 37, e19051-e19051.	1.6	1
42	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nature Communications, 2018, 9, 1614.	12.8	76
43	Combined peripheral natural killer cell and circulating tumor cell enumeration enhance prognostic efficiency in patients with metastatic triple-negative breast cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 315-326.	2.2	14
44	Liquid Biospy: Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles (Small Methods) Tj ETQq. 2018, 2, 1800122. /Overlock	8.6	20
45	Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead-Assisted Flow Cytometry Detection of Tumor-Derived Extracellular Vesicles. Small Methods, 2018, 2, 1800122.	8.6	20
46	Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, 1003-1003.	1.6	0
47	Detection, dynamic monitoring, and resistance mechanism exploration of genomic alterations in circulating cell free tumor DNA (ctDNA) in Chinese metastatic breast cancer (mBC).. Journal of Clinical Oncology, 2018, 36, 1080-1080.	1.6	43
48	Methylomes variation to predict exemestane resistance in advanced breast cancer.. Journal of Clinical Oncology, 2018, 36, e24029-e24029.	1.6	0
49	Plasma PIK3CA ctDNA specific mutation detected by next generation sequencing is associated with clinical outcome in advanced breast cancer. American Journal of Cancer Research, 2018, 8, 1873-1886.	1.4	5
50	Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. American Journal of Cancer Research, 2018, 8, 1837-1846.	1.4	26
51	Plasma CAMK2A predicts chemotherapy resistance in metastatic triple negative breast cancer. International Journal of Clinical and Experimental Pathology, 2018, 11, 650-663.	0.5	3
52	Identification of recurrent <scp>BRCA</scp> 1 mutation and its clinical relevance in Chinese Triple-negative breast cancer cohort. Cancer Medicine, 2017, 6, 547-554.	2.8	11
53	Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial. Lancet Oncology, The, 2017, 18, 371-383.	10.7	43
54	Peptide-Functionalized Nanomaterials for the Efficient Isolation of HER2-Positive Circulating Tumor Cells. ACS Applied Materials & Interfaces, 2017, 9, 18423-18428.	8.0	47

#	ARTICLE	IF	CITATIONS
55	Strategies and Progress of Endocrine Therapy for Patients with Metastatic Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 403-418.	1.6	4
56	Precisely Enumerating Circulating Tumor Cells Utilizing a Multi-Functional Microfluidic Chip and Unique Image Interpretation Algorithm. <i>Theranostics</i> , 2017, 7, 4710-4721.	10.0	14
57	Efficacy and safety of trastuzumab combined with chemotherapy for first-line treatment and beyond progression of HER2-overexpressing advanced breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2016, 28, 330-338.	2.2	17
58	First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. <i>Oncology Letters</i> , 2015, 9, 987-993.	1.8	7
59	National consensus in China on diagnosis and treatment of patients with advanced breast cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 242.	1.7	14
60	Capecitabine maintenance therapy for XT chemotherapy-sensitive patients with metastatic triple-negative breast cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2014, 26, 550-7.	2.2	3
61	Differential impact of tumor-infiltrating immune cells on basal and luminal cells: implications for tumor invasion and metastasis. <i>Anticancer Research</i> , 2014, 34, 6363-80.	1.1	9